Liquidia Corporation is a biopharmaceutical company based in North Carolina. They develop and manufacture products to address unmet patient needs in the United States. Their main product candidate is YUTREPIA, an inhaled dry powder formulation used to treat pulmonary arterial hypertension. They also distribute generic treprostinil injection in the US. Founded in 2004, Liquidia Corporation focuses on improving patient outcomes through innovative pharmaceutical solutions.